VA-FLIR-SYSTEMS
7.1.2020 13:02:06 CET | Business Wire | Press release
FLIR Systems, Inc. (NASDAQ: FLIR) and ANSYS (NASDAQ: ANSS) are collaborating to deliver superior hazard detection capabilities for assisted driving and autonomous vehicles (AVs) — empowering automakers to deliver unprecedented vehicle safety. Through this collaboration, FLIR will integrate a fully physics-based thermal sensor into ANSYS’ leading-edge driving simulator to model, test, and validate thermal camera designs within an ultra-realistic virtual world. The new solution will reduce original equipment manufacturers’ (OEM) development time by optimizing thermal camera placement for use with tools such as automatic emergency braking (AEB), pedestrian detection, and within future AVs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200107005299/en/
Having the ability to test in virtual environments complements the existing systems available to FLIR customers and partners, including the FLIR automotive development kit (ADK™) featuring a FLIR Boson® thermal camera, the FLIR starter thermal dataset and the regional, city-specific thermal datasets. The FLIR thermal dataset programs were created for machine learning in advanced driver assistance development (ADAS), AEB, and AV systems.
The current AV and ADAS sensors face challenges in darkness or shadows, sun glare and inclement weather such as most fog. Thermal cameras, however, can effectively detect and classify objects in these conditions. Integrating FLIR Systems’ thermal sensor into ANSYS® VRXPERIENCE® enables simulation of thousands of driving scenarios across millions of miles in mere days. Furthermore, engineers can simulate difficult-to-produce scenarios where thermal provides critical data, including detecting pedestrians in crowded, low-contrast environments.
“By adding ANSYS’ industry-leading simulation solutions to the existing suite of tools for physical testing, engineers, automakers, and automotive suppliers can improve the safety of vehicles in all types of driving conditions,” said Frank Pennisi, President of the Industrial Business Unit at FLIR Systems. “The industry can also recreate corner cases that drivers can see every day but are difficult to replicate in physical environments, paving the way for improved neural networks and the performance of safety features such as AEB.”
“FLIR Systems’ recognizes the limitations of relying solely on gathering machine learning datasets in the physical world to make automotive thermal cameras as safe and reliable as possible for automotive uses,” said Eric Bantegnie, Vice president and General Manager at ANSYS. “Now with ANSYS solutions, FLIR can further empower automakers to speed the creation and certification of assisted-driving systems with thermal cameras.”
In addition to the city-specific data sets, FLIR has more than a decade of experience in the automotive industry. FLIR has provided more than 700,000 thermal sensors as part of its night vision warning systems for a variety of carmakers, including GM, Audi and Mercedes-Benz. Also, FLIR recently announced that its thermal sensor has been selected by Veoneer, a tier-one automotive supplier, for its level-four AV production contract with a top global automaker, planned for 2021.
FLIR Systems’ thermal-enhanced demonstration car, along with other innovative FLIR products, will be on display at the FLIR booth #8528 during the 2020 Consumer Electronics Show in Las Vegas, Nevada from January 6 - 10.
For more information on FLIR Systems’ automotive solutions, please visit https://www.flir.com/safercars .
About FLIR Systems, Inc.
Founded in 1978, FLIR Systems is a world-leading industrial technology company focused on intelligent sensing solutions for defense, industrial, and commercial applications. FLIR Systems’ vision is to be “The World’s Sixth Sense," creating technologies to help professionals make more informed decisions that save lives and livelihoods. For more information, please visit www.flir.com and follow @flir.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005299/en/
Contact:
Media Contact: Tim McDowd (503) 498-3146 Tim.McDowd@flir.com
Investor Relations: Lasse Glassen Addo Investor Relations Phone: 424-238-6249 Email: lglassen@addoir.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom